Trends and outcomes of pulmonary arterial hypertension–related hospitalizations in the United States: Analysis of the nationwide inpatient sample database from 2001 through 2012

JAMA Cardiology

Volumn 1, Issue 9, 2016, Pages 1021-1029

  Anand, Vidhu ^a   Roy, Samit S ^a   Archer, Stephen L ^b   Weir, E Kenneth ^a   Garg, Sushil Kumar ^a   Duval, Sue ^a   Thenappan, Thenappan ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE KIDNEY FAILURE; ACUTE RESPIRATORY FAILURE; ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; CARDIOGENIC SHOCK; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DATA BASE; DIABETES MELLITUS; ELECTROLYTE DISTURBANCE; FEMALE; HEALTH CARE COST; HEART ARRHYTHMIA; HOSPITAL MORTALITY; HOSPITALIZATION; HUMAN; HYPERTENSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SEX DIFFERENCE; TEACHING HOSPITAL; TREND STUDY; UNITED STATES; VERY ELDERLY;

EID: 85022163825     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.3591     Document Type: Article

References (28)

1. Galiè N, Torbicki A, Barst R, et al; Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J. 2004;25(24):2243-2278.
2. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1): 67-119.
3. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30(1):104-109.
4. Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries. Chest. 2011;139(1): 128-137.
5. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-1030.
6. Escribano-Subias P, Blanco I, López-Meseguer M, et al; REHAP investigators. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012;40(3):596-603.
7. Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012;186(8):790-796.
8. Jansa P, Jarkovsky J, Al-Hiti H, et al. Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulm Med. 2014;14:45.
9. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010;35(5): 1079-1087.
10. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164-172.
11. Burke JP, Hunsche E, Régulier E, Nagao M, Buzinec P, Drake Iii W. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study. Am J Manag Care. 2015;21(3)(suppl):s47-s58.
12. Burger CD, Long PK, Shah MR, et al. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL Registry. Chest. 2014; 146(5):1263-1273.
13. Copher R, Cerulli A, Watkins A, Laura Monsalvo M. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. J Med Econ. 2012;15(5):947-955.
14. Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population. Appl Health Econ Health Policy. 2011;9(5):293-303.
15. Campo A, Mathai SC, Le Pavec J, et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J. 2011; 38(2):359-367.
16. Haddad F, Peterson T, Fuh E, et al. Characteristics and outcome after hospitalization for acute right heart failure in patients with pulmonary arterial hypertension. Circ Heart Fail. 2011;4(6):692-699.
17. Sztrymf B, Souza R, Bertoletti L, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J. 2010;35(6):1286-1293.
18. Healthcare Utilization Project. HCUP introduction. https://www.hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2012.jsp. Updated May 16, 2016. Accessed September 15, 2016.
19. Chen J, Dharmarajan K, Wang Y, Krumholz HM. National trends in heart failure hospital stay rates, 2001 to 2009. J Am Coll Cardiol. 2013;61(10): 1078-1088.
20. Healthcare Utilization Project, US Department of Health and Human Services. HCUP method series. 2016. https://www.hcup-us.ahrq.gov/reports/methods/2006_05_NISTrendsReport _1988-2004.pdf. Accessed September 15, 2016.
21. Channick RN, Delcroix M, Ghofrani HA, et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail. 2015;3(1): 1-8.
22. Mehari A, Valle O, Gillum RF. Trends in pulmonary hypertension mortality and morbidity. Pulm Med. 2014;2014:105864.
23. Lacey MBP, Buzinec P, Hunsche E, et al. Pulmonary hypertension–related rehospitalization among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension in the US. Paper presented at: Academy of Managed Care Pharmacy Nexus Meeting; October 15, 2013; San Antonio, Texas.
24. Thenappan T, Ryan JJ, Archer SL. Evolving epidemiology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186(8):707-709.
25. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448-456.
26. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007;30(6):1103-1110.
27. Krasuski RA, Hart SA, Smith B, Wang A, Harrison JK, Bashore TM. Association of anemia and long-term survival in patients with pulmonary hypertension. Int J Cardiol. 2011;150(3):291-295.
28. Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Chest. 2013;144(1): 169-176.